Table of Contents Author Guidelines Submit a Manuscript
Computational and Mathematical Methods in Medicine
Volume 2013 (2013), Article ID 856897, 6 pages
http://dx.doi.org/10.1155/2013/856897
Research Article

Analysis of a Single Hemodialysis on Phosphate Removal of the Internal Fistula Patients by Mathematical and Statistical Methods

1Departments of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
2Departments of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China

Received 14 May 2013; Revised 7 September 2013; Accepted 30 September 2013

Academic Editor: Tianye Niu

Copyright © 2013 Qiyao Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Floege, J. Kim, E. Ireland et al., “Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population,” Nephrology Dialysis Transplantation, vol. 26, no. 6, pp. 1948–1955, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Raggi, A. Boulay, S. Chasan-Taber et al., “Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease?” Journal of the American College of Cardiology, vol. 39, no. 4, pp. 695–701, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. P. A. U. Torres and M. de Broe, “Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease,” Kidney International, vol. 82, no. 1, pp. 19–25, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. M. A. Mason and B. M. Shepler, “Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis,” Pharmacotherapy, vol. 30, no. 7, pp. 741–748, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Boero, C. Rollino, C. Massara et al., “The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study,” American Journal of Kidney Diseases, vol. 42, no. 1, pp. 67–75, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. S.-J. Yoon, S. Park, C. Park et al., “Association of soluble receptor for advanced glycation end-product with increasing central aortic stiffness in hypertensive patients,” Coronary Artery Disease, vol. 23, no. 2, pp. 85–90, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Iijima, “An active, cell-mediated process, resembling osteogenesis in molecular mechanism of vascular calcification,” Japanese Journal of Clinical Medicine, vol. 69, no. 7, pp. 1220–1227, 2011. View at Google Scholar · View at Scopus
  8. G. A. Block and F. K. Port, “Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management,” American Journal of Kidney Diseases, vol. 35, no. 6, pp. 1226–1237, 2000. View at Google Scholar · View at Scopus
  9. J. Silver, R. Kilav, A. Sela-Brown, and T. Naveh-Many, “Molecular mechanisms of secondary hyperparathyroidism,” Pediatric Nephrology, vol. 14, no. 7, pp. 626–628, 2000. View at Google Scholar · View at Scopus
  10. H. H. Malluche and M. C. Monier-Faugere, “Understanding and managing hyperphosphatemia in patients with chronic renal disease,” Clinical Nephrology, vol. 52, no. 5, pp. 267–277, 1999. View at Google Scholar · View at Scopus
  11. N. W. Levin and N. A. Hoenich, “Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients,” Current Opinion in Nephrology and Hypertension, vol. 10, no. 5, pp. 563–568, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Uribarri and M. S. Calvo, “Hidden sources of phosphorus in the typical American diet: does it matter in nephrology?” Seminars in Dialysis, vol. 16, no. 3, pp. 186–188, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Katsumata, K. Kusano, M. Hirata et al., “Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats,” Kidney International, vol. 64, no. 2, pp. 441–450, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. R. M. Lindsay, F. Alhejaili, G. Nesrallah et al., “Calcium and phosphate balance with quotidian hemodialysis,” American Journal of Kidney Diseases, vol. 42, no. 1, supplement, pp. S24–S29, 2003. View at Google Scholar · View at Scopus
  15. I. Musci, G. Hercz, R. Uldall, M. Ouwendyk, R. Francoeur, and A. Pierratos, “Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis,” Kidney International, vol. 53, no. 5, pp. 1399–1404, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. M. K. Kuhlmann, “Management of hyperphosphatemia,” Hemodialysis International, vol. 10, no. 4, pp. 338–345, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Gallar, M. Ortiz, O. Ortega et al., “Factors which influence phosphorus removal in hemodialysis,” Nefrologia, vol. 27, no. 1, pp. 46–52, 2007. View at Google Scholar · View at Scopus
  18. S. Mandolfo, F. Malberti, E. Imbasciati, P. Cogliati, and A. Gauly, “Impact of blood and dialysate flow and surface on performance of new polysulfone hemodialysis dialyzers,” The International Journal of Artificial Organs, vol. 26, no. 2, pp. 113–120, 2003. View at Google Scholar · View at Scopus
  19. A. Kumar, H. J. Mann, M. Keshtgarpour et al., “In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers,” The International Journal of Artificial Organs, vol. 34, no. 11, pp. 1067–1074, 2011. View at Publisher · View at Google Scholar · View at Scopus